Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Abdominal Radiology
Published in: Abdominal Radiology 6/2019

Open Access 01-06-2019

Radiomics in esophageal and gastric cancer

Authors: Bert-Ram Sah, Kasia Owczarczyk, Musib Siddique, Gary J. R. Cook, Vicky Goh

Published in: Abdominal Radiology | Issue 6/2019

Login to get access

Abstract

Esophageal, esophago-gastric, and gastric cancers are major causes of cancer morbidity and cancer death. For patients with potentially resectable disease, multi-modality treatment is recommended as it provides the best chance of survival. However, quality of life may be adversely affected by therapy, and with a wide variation in outcome despite multi-modality therapy, there is a clear need to improve patient stratification. Radiomic approaches provide an opportunity to improve tumor phenotyping. In this review we assess the evidence to date and discuss how these approaches could improve outcome in esophageal, esophago-gastric, and gastric cancer.
Literature
1.
2.
Ajani JA, Winter K, Okawara GS, et al. (2006) Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol 24(24):3953–3958CrossRefPubMed
3.
Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE (2009) Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol 27(30):5062–5067CrossRefPubMed
4.
Cunningham D, Allum WH, Stenning SP, et al. (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355(1):11–20CrossRefPubMed
5.
Claassen YHM, Hartgrink HH, Dikken JL, et al. (2018) Surgical morbidity and mortality after neoadjuvant chemotherapy in the CRITICS gastric cancer trial. Eur J Surg Oncol 44(5):613–619CrossRefPubMed
6.
van Hagen P, Hulshof MC, van Lanschot JJ, et al. (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366(22):2074–2084CrossRefPubMed
7.
Al-Batran SE, Hofheinz RD, Pauligk C, et al. (2016) Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol 17(12):1697–1708CrossRefPubMed
8.
Reynolds JV, Preston SR, O’Neill B, et al. (2017) ICORG 10-14: NEOadjuvant trial in adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS). BMC Cancer 17(1):401CrossRefPubMedPubMedCentral
9.
Miao ZF, Liu XY, Wang ZN, et al. (2018) Effect of neoadjuvant chemotherapy in patients with gastric cancer: a PRISMA-compliant systematic review and meta-analysis. BMC Cancer 18(1):118CrossRefPubMedPubMedCentral
10.
Secrier M, Li X, de Silva N, et al. (2016) Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. Nat Genet 48(10):1131–1141CrossRefPubMedPubMedCentral
11.
12.
13.
Lagergren P, Avery KN, Hughes R, et al. (2007) Health-related quality of life among patients cured by surgery for esophageal cancer. Cancer 110(3):686–693CrossRefPubMed
14.
Hayes T, Smyth E, Riddell A, Allum W (2017) Staging in esophageal and gastric cancers. Hematol Oncol Clin North Am 31(3):427–440CrossRefPubMed
15.
Findlay JM, Bradley KM, Maile EJ, et al. (2015) Pragmatic staging of oesophageal cancer using decision theory involving selective endoscopic ultrasonography, PET and laparoscopy. Br J Surg 102(12):1488–1499CrossRefPubMed
16.
17.
Foley KG, Christian A, Fielding P, Lewis WG, Roberts SA (2017) Accuracy of contemporary oesophageal cancer lymph node staging with radiological-pathological correlation. Clin Radiol 72(8):693el–693e7CrossRef
18.
Meyers BF, Downey RJ, Decker PA, et al. (2007) The utility of positron emission tomography in staging of potentially operable carcinoma of the thoracic esophagus: results of the American College of Surgeons Oncology Group Z0060 trial. J Thorac Cardiovasc Surg 133(3):738–745CrossRefPubMed
19.
Walker AJ, Spier BJ, Perlman SB, et al. (2011) Integrated PET/CT fusion imaging and endoscopic ultrasound in the pre-operative staging and evaluation of esophageal cancer. Mol Imaging Biol 13(1):166–171CrossRefPubMed
20.
Lordick F, Mariette C, Haustermans K, Obermannova R, Arnold D (2016) Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 27(suppl 5):v50–v57CrossRefPubMed
21.
Barber TW, Duong CP, Leong T, et al. (2012) 18F-FDG PET/CT has a high impact on patient management and provides powerful prognostic stratification in the primary staging of esophageal cancer: a prospective study with mature survival data. J Nucl Med 53(6):864–871CrossRefPubMed
22.
Goel R, Subramaniam RM, Wachsmann JW (2017) PET/computed tomography scanning and precision medicine: esophageal cancer. PET Clin 12(4):373–391CrossRefPubMed
23.
24.
le Grange F, Wickers S, Warry A, et al. (2015) Defining the target in cancer of the oesophagus: direct radiotherapy planning with fluorodeoxyglucose positron emission tomography-computed tomography. Clin Oncol (Royal College of Radiologists (Great Britain)) 27(3):160–167CrossRef
25.
Lee G, Hoseok I, Kim SJ, et al. (2014) Clinical implication of PET/MR imaging in preoperative esophageal cancer staging: comparison with PET/CT, endoscopic ultrasonography, and CT. J Nucl Med 55(8):1242–1247CrossRefPubMed
26.
Tixier F, Le Rest CC, Hatt M, et al. (2011) Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer. J Nucl Med 52(3):369–378CrossRefPubMedPubMedCentral
27.
Beukinga RJ, Hulshoff JB, van Dijk LV, et al. (2017) Predicting response to neoadjuvant chemoradiotherapy in esophageal cancer with textural features derived from pretreatment (18)F-FDG PET/CT imaging. J Nucl Med 58(5):723–729CrossRefPubMed
28.
Nakajo M, Jinguji M, Nakabeppu Y, et al. (2017) Texture analysis of (18)F-FDG PET/CT to predict tumour response and prognosis of patients with esophageal cancer treated by chemoradiotherapy. Eur J Nucl Med Mol Imaging 44(2):206–214CrossRefPubMed
29.
Paul D, Su R, Romain M, et al. (2017) Feature selection for outcome prediction in oesophageal cancer using genetic algorithm and random forest classifier. Comput Med Imaging Graph 60:42–49CrossRefPubMed
30.
Foley KG, Hills RK, Berthon B, et al. (2018) Development and validation of a prognostic model incorporating texture analysis derived from standardised segmentation of PET in patients with oesophageal cancer. Eur Radiol 28(1):428–436CrossRefPubMed
31.
Tan S, Kligerman S, Chen W, et al. (2013) Spatial-temporal [(1)(8)F]FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy. Int J Radiat Oncol Biol Phys 85(5):1375–1382CrossRefPubMed
32.
van Rossum PS, Fried DV, Zhang L, et al. (2016) The incremental value of subjective and quantitative assessment of 18F-FDG PET for the prediction of pathologic complete response to preoperative chemoradiotherapy in esophageal cancer. J Nucl Med 57(5):691–700CrossRefPubMed
33.
Yip SS, Coroller TP, Sanford NN, et al. (2016) Use of registration-based contour propagation in texture analysis for esophageal cancer pathologic response prediction. Phys Med Biol 61(2):906–922CrossRefPubMed
34.
Beukinga RJ, Hulshoff JB, Mul VEM, et al. (2018) Prediction of response to neoadjuvant chemotherapy and radiation therapy with baseline and restaging (18)F-FDG PET imaging biomarkers in patients with esophageal cancer. Radiology 287(3):983–992CrossRefPubMed
35.
Hou Z, Ren W, Li S, et al. (2017) Radiomic analysis in contrast-enhanced CT: predict treatment response to chemoradiotherapy in esophageal carcinoma. Oncotarget 8(61):104444–104454CrossRefPubMedPubMedCentral
36.
Ganeshan B, Skogen K, Pressney I, Coutroubis D, Miles K (2012) Tumour heterogeneity in oesophageal cancer assessed by CT texture analysis: preliminary evidence of an association with tumour metabolism, stage, and survival. Clin Radiol 67(2):157–164CrossRefPubMed
37.
Yip C, Landau D, Kozarski R, et al. (2014) Primary esophageal cancer: heterogeneity as potential prognostic biomarker in patients treated with definitive chemotherapy and radiation therapy. Radiology 270(1):141–148CrossRefPubMed
38.
Ba-Ssalamah A, Muin D, Schernthaner R, et al. (2013) Texture-based classification of different gastric tumors at contrast-enhanced CT. Eur J Radiol 82(10):e537–e543CrossRefPubMed
39.
Ma Z, Fang M, Huang Y, et al. (2017) CT-based radiomics signature for differentiating Borrmann type IV gastric cancer from primary gastric lymphoma. Eur J Radiol 91:142–147CrossRefPubMed
40.
Liu S, Liu S, Ji C, et al. (2017) Application of CT texture analysis in predicting histopathological characteristics of gastric cancers. Eur Radiol 27(12):4951–4959CrossRefPubMed
41.
Yoon SH, Kim YH, Lee YJ, et al. (2016) Tumor heterogeneity in human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer assessed by CT texture analysis: association with survival after trastuzumab treatment. PLloS ONE 11(8):e0161278CrossRef
42.
Giganti F, Antunes S, Salerno A, et al. (2017) Gastric cancer: texture analysis from multidetector computed tomography as a potential preoperative prognostic biomarker. Eur Radiol 27(5):1831–1839CrossRefPubMed
43.
Giganti F, Marra P, Ambrosi A, et al. (2017) Pre-treatment MDCT-based texture analysis for therapy response prediction in gastric cancer: Comparison with tumour regression grade at final histology. Eur J Radiol 90:129–137CrossRefPubMed
44.
Liu S, Zhang Y, Chen L, et al. (2017) Whole-lesion apparent diffusion coefficient histogram analysis: significance in T and N staging of gastric cancers. BMC Cancer 17(1):665CrossRefPubMedPubMedCentral
45.
Liu S, Zhang Y, Xia J, et al. (2017) Predicting the nodal status in gastric cancers: the role of apparent diffusion coefficient histogram characteristic analysis. Magn Reson Imaging 42:144–151CrossRefPubMed
46.
Liu S, Zheng H, Zhang Y, et al. (2018) Whole-volume apparent diffusion coefficient-based entropy parameters for assessment of gastric cancer aggressiveness. J Magn Reson Imaging 47(1):168–175CrossRefPubMed
47.
Zhang Y, Chen J, Liu S, et al. (2017) Assessment of histological differentiation in gastric cancers using whole-volume histogram analysis of apparent diffusion coefficient maps. J Magn Reson Imaging 45(2):440–449CrossRefPubMed
48.
Lambin P, Leijenaar RTH, Deist TM, et al. (2017) Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol 14(12):749–762CrossRefPubMed
Metadata
Title
Radiomics in esophageal and gastric cancer
Authors
Bert-Ram Sah
Kasia Owczarczyk
Musib Siddique
Gary J. R. Cook
Vicky Goh
Publication date
01-06-2019
Publisher
Springer US
Published in
Abdominal Radiology / Issue 6/2019
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-018-1724-8

Other articles of this Issue 6/2019

Abdominal Radiology 6/2019 Go to the issue

Hepatobiliary

Comparison of parallel and crossed placement of antennas in microwave ablation of 3–5 cm hepatocellular carcinoma

Review

Multimodality imaging of small bowel neoplasms

OriginalPaper

Radiogenomics in renal cell carcinoma

Hollow Organ GI

Clinical time course and CT detection of metastatic disease to the small bowel

Pancreas

Weight-adapted ultra-low-dose pancreatic perfusion CT: radiation dose, image quality, and perfusion parameters

Review

Current status of the combination therapy of transarterial chemoembolization and local ablation for hepatocellular carcinoma
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits